Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

By P. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, C. Baigent. The Lancet, 2008

1,960 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/5edf254567fcf10dcadabfd6c9fa22b21b24e52c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. A. Goldfine
3. L. Rydén
4. W. Hiatt
5. Cecilia C. Low Wang
6. V. Basevi
7. Connie N. Hess

In Surgery

1. I. Graham
2. A. Goldfine
3. W. Hiatt
4. Cecilia C. Low Wang
5. V. Basevi
6. Connie N. Hess

Citations in the corpus

• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “Meta-analysis has confirmed the benefits of lipid lowering with statins compared with placebo in people with diabetes.(452) A subgroup analysis of 1501 diabetic patients included in the Treating to New Targets (TNT) study, which compared intensive statin therapy (atorvastatin 80 mg) with standard st”
• Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (2016, positive): “A 21% reduction in major vascular events occurred per 1-mmol/L reduction in LDL cholesterol, irrespective of prior history of vascular disease, gender, age, body mass index (BMI), or baseline systolic or diastolic blood pressure, smoking status, estimated glomerular filtration rate, cholesterol, or ”
• Standards of Medical Care in Diabetes—2013 (2012, background): “3 years, demonstrate a 9% proportional reduction in all-cause mortality and 13% reduction in vascular mortality, for each mmol/L reduction in LDL cholesterol (288).”